Incyte
CHMP recommends marketing authorisation for Incyte’s pemigatinib
February 3, 2021Research and Development EMA, Incyte
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the conditional marketing authorisation of Incyte’s pemigatinib for …
Novartis and Incyte’s ruxolitinib fails to show benefit in COVID-19 at Phase 3
December 14, 2020Research and Development, Sales and Marketing COVID-19, Incyte, Novartis
Novartis has unveiled that its JAK 1/2 tyrosine kinase inhibitor ruxolitinib fell short of its main efficacy goal in the …
Jakafi outperforms best available therapy in steroid-refractory/dependent chronic graft-versus-host disease
December 7, 2020Research and Development, Sales and Marketing Incyte, Jakafi, Novartis
The first Phase 3 findings have been revealed for Jakafi (ruxolitinib) in the treatment of steroid-refractory or steroid-dependent chronic graft-versus-host disease …
FDA gives nod for Monjuvi combo for second-line relapsed or refractory diffuse large B-cell lymphoma
August 3, 2020Sales and Marketing FDA, Incyte, Monjuvi, morphosys, pharma
The FDA has awarded MorphoSys and Incyte US approval for their Fc-modified cytolytic CD19-targeting monoclonal antibody Monjuvi (tafasitamab-cxix), when used …
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14
May 7, 2020Sales and Marketing Incyte, Novartis, Tabrecta, pharma
The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta (capmatinib) for the first-line treatment of metastatic non-small …
Incyte’s Pemazyre becomes FDA’s first and only approved unresectable, advanced cholangiocarcinoma treatment
April 20, 2020Sales and Marketing FDA, Incyte, pharma
The FDA has approved the United States’ first and only treatment for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma, …
Incyte’s ruxolitinib cream formulations look strong in Phase 3 atopic dermatitis
April 7, 2020Manufacturing and Production, Research and Development Incyte, atopic dermatitis, ruxolitinib
Incyte has lifted the curtain on promising new Phase 3 data for its 0.75% and 1.5% twice daily cream formulations …
Lilly and Incyte’s atopic dermatitis drug shows promise at Phase 3
February 13, 2020Sales and Marketing Eli Lilly, Incyte, baricitinib, pharma
Eli Lilly and Incyte have pulled back the curtain on Phase 3 data on their oral selective JAK inhibitor baricitinib …
MorphoSys and Incyte forge potential $1.1bn partnership to develop B cell malignancy drug candidate
January 14, 2020Manufacturing and Production, Sales and Marketing Incyte, morphosys, pharma, tafasitamab
MorphoSys and Incyte have joined together in a partnership to develop and commercialise the latter’s anti-CD19 antibody tafasitamab as a …
Incyte’s drug stumbles at Phase 3 in treatment-naive acute graft-versus-host disease
January 6, 2020Research and Development, Sales and Marketing Incyte, pharma, trial failure
Drugmaker Incyte has made it known that its selective JAK1 inhibitor therapy itacitinib fell short at Phase 3 in the …
Lilly’s arthritis drug hits trouble at FDA committee
April 24, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, Incyte, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis
FDA’s advisory committee were openly conflicted about deciding on the safety of Eli Lilly and Incyte’s drug, baricitinib, for the …
Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns
April 20, 2018Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis
Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …
Keytruda combo fails at Phase 3 in metastatic melanoma
April 9, 2018Research and Development, Sales and Marketing Incyte, MSD, keytruda, pharma, trial failure
Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results …
Incyte acquires Ariad’s European operations in $140 million deal
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license
Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …
Incyte buys rights to Eli Lilly’s Ruxolitinib; shares jump
April 7, 2016Research and Development, Sales and Marketing Eli Lilly, Incyte, Licencing, M&A, MA, Novartis
Shares in Incyte Corp (Nasdaq: INCY) soared to close up over 11.5% Wednesday as the company said it has purchased …
Latest content
Five Facts about cardiovascular disease
